Skip to main content
SpringerLink
Log in

Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95(4):563–573. doi:10.1007/s00277-015-2585-7

    Article  CAS  PubMed  Google Scholar 

  2. VENCLEXTA [Prescribing Information] (2016). AbbVie Inc. North Chicago, IL, USA. Genentech USA Inc. South San Francisco, CA, USA

  3. Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, Gerecitano JF, Kipps TJ, Anderson MA, Huang DCS, Darden DE, Gressick LA, Nolan CE, Yang J, Busman TA, Graham AM, Cerri E, Enschede SH, Humerickhouse RA, Roberts AW (2013) Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 31 (No. 15 [May 20 Supplement]):Abst. 7018

  4. Ma S, Seymour JF, Lanasa MC, Kipps TJ, Barrientos JC, Davids MS, Mason-Bright T, Rudersdorf NK, Yang J, Munasinghe W, Zhu M, Cerri E, Enschede SH, Humerickhouse RA, Roberts AW (2014) ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase 1b study. J Clin Oncol 32 (No. 15 [May 20 Supplement]):Abst. 7013

  5. Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Gerecitano JF, Kipps TJ, Anderson MA, Huang DCS, Rudersdorf NK, gressick LA, Montalvo NP, Yang J, Zhu M, Dunbar M, Cerri E, Enschede SH, Humerickhouse RA, Roberts AW (2014) ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control. J Clin Oncol 32 (No. 15 [May 20 Supplement]):Abst. 7015

  6. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre SE, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Bottcher S, Mobasher M, Zhu M, Desai M, Chylla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse RA, Gordon G, Hallek M, Wierda WG (2016) Venetoclax in relapsed/refractory chronic lymphocytic leukemia with 17p deletion: a phase 2, open label, multicenter study. The Lancet Oncology. doi:10.1016/S1470-2045(16)30019-5

  7. Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364(19):1844–1854. doi:10.1056/NEJMra0904569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Medical writing support was provided by Sharanya Ford, PhD, of AbbVie.

Author information

Authors and Affiliations

  1. Peter MacCallum Cancer Centre, St Andrews Place East Melbourne, Melbourne, Victoria, 3002, Australia

    John F. Seymour

Authors
  1. John F. Seymour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John F. Seymour.

Ethics declarations

Conflict of interest

JF Seymour received research funding from AbbVie and Genentech and is a consultant and advisory board member for Roche and Genentech.

AbbVie disclosures: AbbVie provided financial support for the studies and participated in the design, study conduct, analysis and interpretation of data as well as the writing, review and approval of the publication. Venetoclax (ABT-199/GDC-0199) is being developed in collaboration between AbbVie and Genentech.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seymour, J.F. Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia. Ann Hematol 95, 1361–1362 (2016). https://doi.org/10.1007/s00277-016-2695-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2695-x

Keywords

Search

Navigation